^
over1year
Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma. (PubMed, Oncol Rep)
Pharmacological inhibition of EZH2 using EPZ005687 attenuated MB cell viability and reduced the expression of B7‑H3...Further, EZH2 silencing induced apoptosis and reduced colony‑forming ability in MB cells, whereas EZH2 inhibition in MYC‑amplified C17.2 neural stem cells induced G2/M phase arrest while downregulating B7‑H3 expression. Collectively, the current study positions EZH2 as a viable target for the future development of MB treatments and that targeting EZH2 in combination with B7‑H3 immunotherapy may be an effective treatment for halting MB progression.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • CD276 (CD276 Molecule) • MIR29A (MicroRNA 29a)
|
CD276 expression • MYC positive • EZH2 overexpression
|
EPZ005687